Banque Cantonale Vaudoise’s Sarepta Therapeutics SRPT Stock Holding History

Banque Cantonale Vaudoise’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-467	Closed	-$35K	–	1287
2022 Q2	$35K	Buy	467 +39	+9%	+$2.87K	﹤0.01%	1059
2022 Q1	$33K	Sell	428 -845	-66%	-$64.7K	﹤0.01%	1103
2021 Q4	$115K	Sell	1,273 -296	-19%	-$25.3K	﹤0.01%	940
2021 Q3	$145K	Sell	1,569 -2,262	-59%	-$174K	0.01%	872
2021 Q2	$298K	Sell	3,831 -1,381	-26%	-$105K	0.01%	748
2021 Q1	$389K	Buy	5,212 +208	+4%	+$19.2K	0.02%	605
2020 Q4	$852K	Sell	5,004 -2,058	-29%	-$305K	0.05%	345
2020 Q3	$991K	Buy	7,062 +1,533	+28%	+$233K	0.06%	263
2020 Q2	$887K	Buy	5,529 +2,605	+89%	+$354K	0.06%	280
2020 Q1	$286K	Sell	2,924 -225	-7%	-$25.7K	0.02%	527
2019 Q4	$406K	Buy	+3,149	New	+$318K	0.03%	530

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Banque Cantonale Vaudoise's SRPT Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 467 shares — an estimated $35K sold.

Banque Cantonale Vaudoise first reported a position in SRPT in Q4 2019 and held it in 11 quarters. The position peaked at $991K in Q3 2020. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

Banque Cantonale Vaudoise reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 467 Sarepta Therapeutics shares in Q3 2022, an estimated $35K.
Banque Cantonale Vaudoise first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 11 quarters.
Banque Cantonale Vaudoise's Sarepta Therapeutics position peaked at $991K in Q3 2020.
375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.